GeoVax Labs, Inc. (GOVX) stock
GOVXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.99−0.02 (-1.00%)
Close on Nov 18, 2026Market cap $14.66MP/E –Yield –
GeoVax Labs operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
GeoVax Labs's operating income for the twelve months ending Jun 30, 2026 was -$20.53M. For fiscal 2025 it was -$21.64M. The highest annual figure on record is -$2.14M in fiscal 2012.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$21.64M | – |
| FY2024 | Dec 31, 2024 | -$25.14M | – |
| FY2023 | Dec 31, 2023 | -$26.74M | – |
| FY2022 | Dec 31, 2022 | -$14.03M | – |
| FY2021 | Dec 31, 2021 | -$18.75M | – |
| FY2020 | Dec 31, 2020 | -$2.82M | – |
| FY2019 | Dec 31, 2019 | -$2.37M | – |
| FY2018 | Dec 31, 2018 | -$2.56M | – |
| FY2017 | Dec 31, 2017 | -$2.17M | – |
| FY2016 | Dec 31, 2016 | -$3.27M | – |
| FY2015 | Dec 31, 2015 | -$2.69M | – |
| FY2014 | Dec 31, 2014 | -$2.74M | – |
| FY2013 | Dec 31, 2013 | -$2.29M | – |
| FY2012 | Dec 31, 2012 | -$2.14M | – |
| FY2011 | Dec 31, 2011 | -$2.35M | – |
| FY2010 | Dec 31, 2010 | -$2.77M | – |
| FY2009 | Dec 31, 2009 | -$3.32M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$4.44M | – |
| Q1 FY2026 | Mar 31, 2026 | -$5.27M | – |
| Q4 FY2025 | Dec 31, 2025 | -$4.44M | – |
| Q3 FY2025 | Sep 30, 2025 | -$6.37M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.42M | – |
| Q1 FY2025 | Mar 31, 2025 | -$5.41M | – |
| Q4 FY2024 | Dec 31, 2024 | -$8.34M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.85M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.06M | – |
| Q1 FY2024 | Mar 31, 2024 | -$5.88M | – |
| Q4 FY2023 | Dec 31, 2023 | -$7.69M | – |
| Q3 FY2023 | Sep 30, 2023 | -$8.60M | – |
| Q2 FY2023 | Jun 30, 2023 | -$6.18M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.27M | – |
| Q4 FY2022 | Dec 31, 2022 | -$5.39M | – |
| Q3 FY2022 | Sep 30, 2022 | -$3.97M | – |
| Q2 FY2022 | Jun 30, 2022 | -$2.24M | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.43M | – |
| Q4 FY2021 | Dec 31, 2021 | -$13.74M | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.95M | – |
| Q2 FY2021 | Jun 30, 2021 | -$1.49M | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.56M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.34M | – |
| Q3 FY2020 | Sep 30, 2020 | -$436.31K | – |
| Q2 FY2020 | Jun 30, 2020 | -$448.11K | – |
| Q1 FY2020 | Mar 31, 2020 | -$595.30K | – |
| Q4 FY2019 | Dec 31, 2019 | -$591.07K | – |
| Q3 FY2019 | Sep 30, 2019 | -$425.94K | – |
| Q2 FY2019 | Jun 30, 2019 | -$653.94K | – |
| Q1 FY2019 | Mar 31, 2019 | -$701.55K | – |
| Q4 FY2018 | Dec 31, 2018 | -$634.33K | – |
| Q3 FY2018 | Sep 30, 2018 | -$667.33K | – |
| Q2 FY2018 | Jun 30, 2018 | -$638.13K | – |
| Q1 FY2018 | Mar 31, 2018 | -$622.92K | – |
| Q4 FY2017 | Dec 31, 2017 | -$517.22K | – |
| Q3 FY2017 | Sep 30, 2017 | -$590.35K | – |
| Q2 FY2017 | Jun 30, 2017 | -$518.15K | – |
| Q1 FY2017 | Mar 31, 2017 | -$548.73K | – |
| Q4 FY2016 | Dec 31, 2016 | -$935.80K | – |
| Q3 FY2016 | Sep 30, 2016 | -$464.54K | – |
See a number that looks wrong?